2.7 OSHA Bloodborne Pathogens & Post-Exposure Management

2.7 OSHA Bloodborne Pathogens & Post-Exposure Management

Quick Answer: The OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030) requires employers to maintain a written Exposure Control Plan (ECP), enforce engineering controls (safety-engineered needles, puncture-resistant sharps boxes) and work practice controls (no recapping), and offer the Hepatitis B vaccine free within 10 days of assignment. The percutaneous transmission risk hierarchy is: HBV (6%–30%) > HCV (1.8%) > HIV (0.3%). Following a needlestick exposure, the immediate protocol is: 1. Wash site with soap and water for several minutes (flush eyes for 15 min) -> 2. Report immediately to supervisor -> 3. Confidential medical evaluation, baseline testing, and HIV PEP within 2 hours (up to 72 hours) -> 4. Log incident on the Sharps Injury Log.

Bloodborne pathogens are infectious microorganisms present in human blood and other potentially infectious materials (OPIM) that can cause severe, life-threatening human disease. Because phlebotomists perform daily percutaneous vascular punctures, mastery of OSHA mandates and immediate exposure management protocols is essential for clinical practice and certification.

---

The OSHA Bloodborne Pathogens Standard (29 CFR 1910.1030)

Promulgated by the Occupational Safety and Health Administration (OSHA), this federal regulation mandates that healthcare employers implement comprehensive safeguards to protect employees with potential occupational exposure to blood, semen, vaginal secretions, cerebrospinal fluid (CSF), synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, amniotic fluid, and any body fluid visibly contaminated with blood.

+-------------------------------------------------------------------------+
|               OSHA BLOODBORNE PATHOGENS STANDARD PILLARS                |
+-------------------------------------------------------------------------+
| Exposure Control Plan | Written protocol, reviewed/updated annually     |
| Engineering Controls  | Safety needles, sharps bins, plastic tubes      |
| Work Practice Control | No two-handed recapping, hand hygiene, no eating|
| Hepatitis B Vaccine   | Provided free of charge within 10 days of work  |
| Universal Precautions | Treat all human blood and OPIM as infectious    |
| Post-Exposure Follow  | Immediate wound care, PEP, confidential eval    |
+-------------------------------------------------------------------------+

The Exposure Control Plan (ECP)

Every healthcare facility must maintain a written, site-specific Exposure Control Plan accessible to all employees. Key ECP requirements include:

• Annual Review and Update: The plan must be reviewed and updated at least annually and whenever new procedures, technologies, or positions modify occupational exposure.
• Frontline Employee Input: Employers must solicit input from non-managerial, frontline healthcare workers (including phlebotomists) regarding the identification, evaluation, and selection of effective engineering and work practice controls.
• Exposure Determination: A documented list of all job classifications and procedures where occupational exposure to bloodborne pathogens occurs.
• Implementation Schedules: Documented methods for compliance, including Hepatitis B vaccination, sharps safety protocols, post-exposure evaluations, biohazard hazard communication, and annual employee training.

---

Engineering Controls vs. Work Practice Controls

OSHA requires employers to eliminate or minimize employee exposure using a hierarchy of safety controls. Engineering controls sit higher in the hierarchy than work practice controls.

+-------------------------------------------------------------------------+
|            ENGINEERING CONTROLS vs WORK PRACTICE CONTROLS               |
+-------------------------------------------------------------------------+
| ENGINEERING CONTROLS (Physical Devices)| WORK PRACTICE CONTROLS (Behavior)| 
+----------------------------------------+--------------------------------+
| - Safety-shielded venipuncture needles | - Strict ban on recapping       |
| - Retractable capillary lancets        | - Immediate hand hygiene       |
| - Puncture-resistant sharps containers | - Disposing sharps immediately  |
| - Plastic vacuum tubes (vs. glass)     | - No eating/drinking in lab    |
| - Self-blunting butterfly needles      | - No mouth pipetting           |
+----------------------------------------+--------------------------------+

Engineering Controls (Device Technology)

Engineering controls are physical mechanisms, devices, or pieces of equipment that isolate, contain, or eliminate the bloodborne pathogen hazard from the workplace:

• Safety-Engineered Needles: Needle holders with hinged protective shields, active sliding sheaths, or push-button needle retraction mechanisms that enclose the sharp point immediately after use.
• Safety Lancets: Spring-loaded, retractable blade or needle lancets where the sharp is permanently locked inside the plastic housing before and after skin puncture.
• Sharps Disposal Units: Rigid, puncture-resistant, leak-proof containers located at point-of-use.
• Plastic Blood Collection Tubes: Polyethylene terephthalate (PET) tubes replacing fragile glass tubes to prevent shatter injuries during centrifugation.

Work Practice Controls (Behavioral Protocols)

Work practice controls are behavioral rules, policies, and procedural steps that reduce the likelihood of exposure by altering the way a clinical task is performed:

• Ban on Two-Handed Recapping: Never use two hands to recap a contaminated needle. If recapping is clinically essential (e.g., specialized arterial blood gas syringe preparation without safety shields), only a mechanical device or the one-handed scoop technique is permitted.
• Immediate Point-of-Use Disposal: Discarding used sharps into a sharps container immediately upon withdrawal without setting them down on trays or counters.
• Prohibition of Food/Drink: Strictly prohibiting eating, drinking, smoking, applying cosmetics or lip balm, and handling contact lenses in work areas where blood or OPIM are present.
• No Pipetting by Mouth: Prohibiting mouth suctioning for specimen transfer.
• Handwashing Discipline: Washing hands immediately after glove removal or after any direct contact with blood/body fluids.

---

Hepatitis B Immunization Mandate

Hepatitis B Virus (HBV) is a major occupational hazard for healthcare workers, causing chronic hepatitis, cirrhosis, and hepatocellular carcinoma. OSHA establishes strict employer vaccination rules:

• Free of Charge: The Hepatitis B vaccination series (typically 3 intramuscular doses administered at 0, 1, and 6 months) must be made available to all employees with occupational exposure risk at no cost to the employee.
• Timing: The vaccine must be offered within 10 working days of initial assignment to a job category involving exposure.
• Mandatory Declination Form: An employee has the legal right to decline the Hepatitis B vaccine. If an employee declines, they must sign the standardized OSHA Hepatitis B Vaccine Declination Form. If the employee later decides to accept the vaccination series while still in an occupationally exposed role, the employer must provide the vaccine series free of charge upon request.
• Post-Vaccination Titer Check: Between 1 and 2 months after the final dose of the 3-dose series, healthcare workers must undergo a quantitative anti-HBs (hepatitis B surface antibody) titer test. A titer of ≥10 mIU/mL confirms protective immunity. Non-responders (<10 mIU/mL) must undergo a second 3-dose series and repeat titer testing; individuals who fail to respond after two series are classified as non-responders and require specific post-exposure protocol planning.

---

Bloodborne Pathogens Transmission Risk Hierarchy

The risk of seroconversion following an accidental percutaneous needlestick injury with blood from an infected source patient varies significantly based on viral concentration, pathogen characteristics, and needle geometry (hollow-bore vs. solid needle):

+-------------------------------------------------------------------------+
|          PERCUTANEOUS TRANSMISSION RISK HIERARCHY (NEEDLESTICK)         |
+-------------------------------------------------------------------------+
| Pathogen | Percutaneous Risk | Environmental Stability | Vaccine / PEP  |
+----------+-------------------+-------------------------+----------------+
| HBV      | 6% to 30%         | Stable >7 days on dry   | Vaccine + HBIG |
|          | (HBeAg-positive)  | surfaces                | available      |
+----------+-------------------+-------------------------+----------------+
| HCV      | ~1.8% (1% to 2%)  | Stable up to 4-7 days   | No vaccine/PEP;|
|          |                   |                         | DAA cure       |
+----------+-------------------+-------------------------+----------------+
| HIV      | ~0.3% (1 in 300)  | Fragile, dries quickly  | 28-day PEP     |
|          | (0.09% mucocutan.)|                         | (start <2 hrs) |
+-------------------------------------------------------------------------+

1. Hepatitis B Virus (HBV): The transmission risk is 6% to 30% from an HBeAg-positive source patient. HBV possesses high viral titers in blood and is exceptionally stable in the environment, remaining infectious on dry surfaces, phlebotomy chairs, or equipment for at least 7 days.
2. Hepatitis C Virus (HCV): The transmission risk is approximately 1.8% (range 1% to 2%). HCV is the most common chronic bloodborne infection in the United States. There is currently no post-exposure prophylaxis or vaccine for HCV; management relies on baseline and follow-up RNA testing, followed by direct-acting antiviral (DAA) therapy if transmission occurs.
3. Human Immunodeficiency Virus (HIV): The transmission risk is approximately 0.3% (1 in 300) following a percutaneous exposure to HIV-infected blood, and 0.09% following mucous membrane exposure. Risk increases with hollow-bore large-gauge needles, deep intramuscular punctures, visible blood on the device, or high source viral loads.

---

Immediate Step-by-Step Post-Exposure Protocol

When a percutaneous needlestick, puncture, splash, or mucous membrane exposure occurs, every second counts. The phlebotomist must execute the following sequential protocol immediately:

+-------------------------------------------------------------------------+
|               IMMEDIATE POST-EXPOSURE ACTION WORKFLOW                   |
+-------------------------------------------------------------------------+
| STEP 1: IMMEDIATE WOUND CARE & DECONTAMINATION                          |
| - Puncture: Wash with soap and running water for several minutes        |
| - Eye/Mucous Splash: Flush at eyewash station for minimum 15 minutes    |
| - DO NOT squeeze/milk wound excessively; DO NOT apply caustic bleach    |
+-------------------------------------------------------------------------+
                                     |
                                     v
+-------------------------------------------------------------------------+
| STEP 2: IMMEDIATE REPORTING TO SUPERVISOR                               |
| - Notify charge supervisor/occupational health immediately              |
| - Identify source patient and exact circumstances of exposure           |
+-------------------------------------------------------------------------+
                                     |
                                     v
+-------------------------------------------------------------------------+
| STEP 3: MEDICAL EVALUATION, TESTING & PROPHYLAXIS                       |
| - Source testing: HIV, HBsAg, HCV antibody (with consent)               |
| - Employee baseline testing: HIV, anti-HBs, HCV antibody                |
| - HIV PEP: Initiate within 2 hours (up to 72 hours max), 28-day regimen |
| - HBV PEP: Administer HBIG + vaccine within 24 hours if unimmunized     |
+-------------------------------------------------------------------------+
                                     |
                                     v
+-------------------------------------------------------------------------+
| STEP 4: DOCUMENTATION & SHARPS INJURY LOGGING                           |
| - Complete OSHA 300 log and Sharps Injury Log (confidential)            |
+-------------------------------------------------------------------------+

Step 1: Immediate Decontamination and First Aid

• Percutaneous Puncture/Cut: Wash the wound thoroughly with soap and copious running water for several minutes. Allow normal bleeding to flow freely. Do NOT excessively squeeze, milk, or massage the puncture, as this induces local tissue trauma and can draw contaminants deeper into capillaries. Do NOT apply caustic chemicals, bleach, or pure disinfectants into open tissue.
• Mucous Membrane Exposure (Eyes, Nose, Mouth): Flush the exposed mucous membranes or eyes at an emergency eyewash station or with sterile isotonic saline/water for a minimum of 15 minutes.
• Skin Exposure (Non-Intact Skin): Wash the area thoroughly with soap and water.

Step 2: Immediate Supervisor Reporting

• Notify the immediate supervisor, charge nurse, or laboratory manager immediately following initial wound decontamination. Immediate reporting ensures swift administrative clearance for source patient testing and expedited medical evaluation.

Step 3: Medical Evaluation, Testing, and Prophylaxis

• Confidential Evaluation: The exposed employee is directed immediately to the Occupational Health Department or Emergency Department for a confidential clinical evaluation.
• Source Patient Testing: The source patient is identified, and their blood is tested for HBsAg, HCV antibody, and HIV antibody (subject to patient consent in accordance with state law).
• Employee Baseline Testing: Baseline blood samples are drawn from the exposed phlebotomist to test for HIV antibody, anti-HBs, and HCV antibody. If the employee consents to blood collection but declines immediate HIV testing, the sample must be preserved for at least 90 days in case the employee requests testing later.
• HIV Post-Exposure Prophylaxis (PEP): If the source patient is HIV-positive or high-risk unknown, a 3-drug antiretroviral PEP regimen (e.g., tenofovir, emtricitabine, plus raltegravir or dolutegravir) must be initiated as soon as possible, ideally within 2 hours of exposure (and no later than 72 hours). The full PEP course is taken for 28 days with clinical monitoring.
• Hepatitis B PEP: If an exposed worker is unvaccinated or a known non-responder, Hepatitis B Immune Globulin (HBIG) must be administered within 24 hours along with initiating the Hepatitis B vaccine series.

Step 4: Documentation & Sharps Injury Log

Under the Needlestick Safety and Prevention Act, employers must maintain a Sharps Injury Log (recorded alongside the OSHA 300 / 300A logs) detailing:

1. The type and brand of the device involved in the incident (e.g., 21-gauge safety butterfly needle, Manufacturer X).
2. The department or work area where the incident occurred (e.g., Outpatient Draw Station 3).
3. A clear, objective explanation of how the exposure incident occurred (e.g., needle rebounded while attempting to engage safety shield).
4. All employee medical records and exposure logs must be kept confidential and retained for the duration of employment plus 30 years.